The DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index.
Dapagliflozin’s Effects on Glycemia and Cardiovascular Risk Factors in High-Risk Patients With Type 2 Diabetes: A 24-Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study With a 28-Week Extension
Open accessAbstract
OBJECTIVE: To assess the efficacy and safety of dapagliflozin, a selective sodium-glucose cotransporter 2 inhibitor, compared with placebo in patients with type 2 diabetes (T2D), documented pre-existing cardiovascular disease (CVD), and a history of hypertension. RESEARCH DESIGN AND METHODS: Patients (N = 922) were randomized to receive 10 mg dapagliflozin or placebo in a double-blind trial for 24 weeks, followed by a 28-week extension period. In patients receiving insulin, the insulin dose was reduced by 25% at randomization. Patients were stratified by age, insulin use, and time from the most recent qualifying cardiovascular (CV) event. Co-primary end points were a change from baseline in hemoglobin A1c (HbA1c) and the proportion of patients achieving a combined reduction in HbA1c of ≥0.5% (5.5 mmol/mol), body weight (BW) of ≥3%, and systolic blood pressure (SBP) of ≥3 mmHg. RESULTS: At 24 weeks, dapagliflozin significantly reduced HbA1c (−0.38% [−4.2 mmol/mol]) from baseline (8.18%) compared with a slight increase with placebo from baseline (8.08%) (0.08% [0.9 mmol/mol]). Significantly more patients met the three-item end point with treatment with dapagliflozin than with placebo (11.7% vs. 0.9%, respectively). Changes were maintained over 52 weeks. Although ∼42% of patients were ≥65 years old, similar results were observed in both age-stratified groups. Serious adverse events, hypoglycemia, urinary tract infections, and cardiac disorders were similar between groups. Adverse events of hypotension, dehydration, hypovolemia, genital infection, and renal failure or impairment occurred more often with dapagliflozin treatment. CONCLUSIONS: In this study that evaluated T2D patients who were at high risk for future CVD events, dapagliflozin administration had significantly greater effects in reducing HbA1c, BW, and SBP, without adversely impacting CV safety when compared with placebo treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The addition of metabolic surgery (148), weight loss medications (149), and glucose-lowering agents that promote weight loss (150) can also be used as an adjunct to lifestyle interventions, resulting in greater weight loss that is maintained for a longer period of time.”
From Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report (2019) · cites this paper as [150]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Standards of medical care in diabetes—2013
American Diabetes Association (2013) · Diabetes Care · doi:10.2337/dc13-s011 · Cited by 4,369
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetologia · doi:10.1007/s00125-012-2534-0 · Cited by 3,919
Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach
Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2012) · Diabetes Care · doi:10.2337/dc12-0413 · Cited by 3,207
(2013) · European Heart Journal · doi:10.1093/eurheartj/eht108 · Cited by 1,955
Whelton, P. K. (2002) · JAMA · doi:10.1001/jama.288.15.1882 · Cited by 1,473
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 860
Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., & List, J. F. (2010) · Diabetes Care · doi:10.2337/dc10-0612 · Cited by 716
(2007) · Endocrine Practice · doi:10.4158/ep.13.s1.1 · Cited by 699
Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes
List, J. F., Woo, V., Morales, E., Tang, W., & Fiedorek, F. T. (2009) · Diabetes Care · doi:10.2337/dc08-1863 · Cited by 698
Research works printed but not linked: 1
- Rodbard, 2007, American Association of Clinical Endocrinologists medical guidelines for clinical practice for the management of diabetes mellitus, Endocr Pract, 13, 1
Cited by
Nutrition Therapy for Adults With Diabetes or Prediabetes: A Consensus Report
Evert, A. B., Dennison, M., Gardner, C. D., Garvey, W. T., Lau, K. H. K., MacLeod, J., Mitri, J., Pereira, R. F., Rawlings, K., Robinson, S., et al. (2019) · Diabetes Care · doi:10.2337/dci19-0014 · Cited by 1,496
Palmer, S. C., Tendal, B., Mustafa, R. A., Vandvik, P. O., Li, S., Hao, Q., Tunnicliffe, D., Ruospo, M., Natale, P., Saglimbene, V., et al. (2021) · BMJ · doi:10.1136/bmj.m4573 · Cited by 679
An update on sodium-glucose co-transporter-2 inhibitors for the treatment of diabetes mellitus
Hsia, D. S., Grove, O., & Cefalu, W. T. (2017) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0000000000000311 · Cited by 508
Self-citationZaccardi, F., Webb, D. R., Htike, Z. Z., Youssef, D., Khunti, K., & Davies, M. J. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12670 · Cited by 489
American Diabetes Association Professional Practice Committee (2022) · Diabetes Care · doi:10.2337/dc22-s005 · Cited by 445
ElSayed, N. A., Aleppo, G., Aroda, V. R., Bannuru, R. R., Brown, F. M., Bruemmer, D., Collins, B. S., Hilliard, M. E., Isaacs, D., Johnson, E. L., et al. (2023) · Diabetes Care · doi:10.2337/dc23-s005 · Cited by 362
American Diabetes Association (2020) · Diabetes Care · doi:10.2337/dc20-s005 · Cited by 339
Toyama, T., Neuen, B. L., Jun, M., Ohkuma, T., Neal, B., Jardine, M. J., Heerspink, H. L., Wong, M. G., Ninomiya, T., Wada, T., et al. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13648 · Cited by 330
American Diabetes Association Professional Practice Committee, ElSayed, N. A., McCoy, R. G., Aleppo, G., Balapattabi, K., Beverly, E. A., Briggs Early, K., Bruemmer, D., Echouffo-Tcheugui, J. B., Eichorst, B., et al. (2025) · Diabetes Care · doi:10.2337/dc25-s005 · Cited by 305
American Diabetes Association (2021) · Diabetes Care · doi:10.2337/dc21-s005 · Cited by 299
“that results in energy deficit in conjunction with weight lossmedications and/or metabolic surgery should be considered to help achieve weight loss and maintenance goals, lower A1C, and reduce CVD risk (84,91,92).”
BackgroundAmerican Diabetes Association Professional Practice Committee, ElSayed, N. A., Aleppo, G., Bannuru, R. R., Beverly, E. A., Bruemmer, D., Collins, B. S., Darville, A., Ekhlaspour, L., Hassanein, M., et al. (2024) · Diabetes Care · doi:10.2337/dc24-s005 · Cited by 285
Dapagliflozin: A Review in Type 2 Diabetes
Dhillon, S. (2019) · Drugs · doi:10.1007/s40265-019-01148-3 · Cited by 243
Storgaard, H., Gluud, L. L., Bennett, C., Grøndahl, M. F., Christensen, M. B., Knop, F. K., & Vilsbøll, T. (2016) · PLOS ONE · doi:10.1371/journal.pone.0166125 · Cited by 237
Donnan, J. R., Grandy, C. A., Chibrikov, E., Marra, C. A., Aubrey-Bassler, K., Johnston, K., Swab, M., Hache, J., Curnew, D., Nguyen, H., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-022577 · Cited by 222
Fernandes, G. C., Fernandes, A., Cardoso, R., Penalver, J., Knijnik, L., Mitrani, R. D., Myerburg, R. J., & Goldberger, J. J. (2021) · Heart Rhythm · doi:10.1016/j.hrthm.2021.03.028 · Cited by 214
Tang, H., Dai, Q., Shi, W., Zhai, S., Song, Y., & Han, J. (2017) · Diabetologia · doi:10.1007/s00125-017-4370-8 · Cited by 206
Li, H.-L., Lip, G. Y. H., Feng, Q., Fei, Y., Tse, Y.-K., Wu, M.-Z., Ren, Q.-W., Tse, H.-F., Cheung, B.-M. Y., & Yiu, K.-H. (2021) · Cardiovascular Diabetology · doi:10.1186/s12933-021-01293-8 · Cited by 188
Cai, X., Yang, W., Gao, X., Chen, Y., Zhou, L., Zhang, S., Han, X., & Ji, L. (2018) · Obesity · doi:10.1002/oby.22066 · Cited by 181
Sonesson, C., Johansson, P. A., Johnsson, E., & Gause-Nilsson, I. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0356-y · Cited by 176
“The efficacy and safety of dapagliflozin has been studied in a wide range of populations as monotherapy or in combination with a variety of other glucose-lowering therapies [19–38].”
BackgroundMethodSelf-citationPetrykiv, S. I., Sjöström, C. D., Greasley, P. J., Xu, J. L., Persson, F., & Heerspink, H. J. L. (2017) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.10180916 · Cited by 159
Pandey, A. K., Okaj, I., Kaur, H., Belley‐Côté, E. P., Wang, J., Oraii, A., Benz, A. P., Johnson, L., Young, J., Wong, J. A., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.121.022222 · Cited by 164
Gedebjerg, A., Almdal, T., Berencsi, K., Rungby, J., Nielsen, J. S., Witte, D. R., Friborg, S. G., Brandslund, I., Vaag, A. A., Beck‐Nielsen, H., et al. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.09.010 · Cited by 170
Weber, M. A., Mansfield, T. A., Alessi, F., Iqbal, N., Parikh, S. J., & Ptaszynska, A. (2015) · Blood Pressure · doi:10.3109/08037051.2015.1116258 · Cited by 131
“sion.[31] However, in the present study, the vast”
Self-citationDekkers, C. C. J., Sjöström, C. D., Greasley, P. J., Cain, V., Boulton, D. W., & Heerspink, H. J. L. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13855 · Cited by 106
Sodium glucose CoTransporter 2 (SGLT2) inhibitors: Current status and future perspective
Madaan, T., Akhtar, M., & Najmi, A. K. (2016) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2016.08.025 · Cited by 119
Dekkers, C. C. J., Wheeler, D. C., Sjöström, C. D., Stefansson, B. V., Cain, V., & Heerspink, H. J. L. (2018) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfx350 · Cited by 102
Fioretto, P., Giaccari, A., & Sesti, G. (2015) · Cardiovascular Diabetology · doi:10.1186/s12933-015-0297-x · Cited by 115
“Moreover, recent findings have demonstrated a remarkably rapid action of dapagliflozin, with reductions in FPG levels within 1 week of treatment [77].”
BackgroundLong, M., Cai, L., Li, W., Zhang, L., Guo, S., Zhang, R., Zheng, Y., Liu, X., Wang, M., Zhou, X., et al. (2017) · Diabetes · doi:10.2337/db17-0934 · Cited by 105
“On the other hand, some hypoglycemic agents also cause negative side effects, such as the increased risk of heart failure hospitalization that is associated with saxagliptin (Sax) (4,5) and the elevated renal failure incidence with dapagliflozin (6).”
BackgroundLawson, C. A., Seidu, S., Zaccardi, F., McCann, G. P., Kadam, U. T., Davies, M. J., Lam, C. S. P., Heerspink, H. J. L., & Khunti, K. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100739 · Cited by 101
“A notable strength of this study is the inclusion of only new onset HF, in an attempt to tease apart the ‘chicken or egg’ relationships among T2D, CKD and HF.”
BackgroundInfluentialMonami, M., Dicembrini, I., & Mannucci, E. (2016) · Acta Diabetologica · doi:10.1007/s00592-016-0892-7 · Cited by 99
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-49525-y · Cited by 106
Tang, H., Fang, Z., Wang, T., Cui, W., Zhai, S., & Song, Y. (2016) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2016.08.061 · Cited by 75
Kanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · UCL Discovery (University College London) · Cited by 71
SGLT2 inhibition: efficacy and safety in type 2 diabetes treatment
Scheen, A. J. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1100167 · Cited by 70
“Changes were maintained over 52 weeks.[124] However, adverse events of hypotension, dehydration, hypovolemia, and renal failure or impairment occurred more often with dapagliflozin treatment, but without adversely impacting cardiovascular safety when compared with placebo treatment.”
BackgroundCai, X., Gao, X., Yang, W., Chen, Y., Zhang, S., Zhou, L., Han, X., & Ji, L. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12760 · Cited by 64
Drake, T. C., Landsteiner, A. M. K., Langsetmo, L., MacDonald, R. H., Anthony, M., Kalinowski, C., Ullman, K. E., Billington, C. J., Kaka, A. S., Sultan, S., et al. (2024) · Annals of Internal Medicine · doi:10.7326/m23-1490 · Cited by 73
Li, D., Yang, J. Y., Wang, T., Shen, S., & Tang, H. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2018.02.001 · Cited by 69
Systematic review and meta-analysis: SGLT2 inhibitors, blood pressure and cardiovascular outcomes
Benham, J. L., Booth, J. E., Sigal, R. J., Daskalopoulou, S. S., Leung, A. A. C., & Rabi, D. M. (2021) · IJC Heart & Vasculature · doi:10.1016/j.ijcha.2021.100725 · Cited by 76
Effect of Dapagliflozin Treatment on Fluid and Electrolyte Balance in Diabetic Rats
Chen, L., LaRocque, L. M., Efe, O., Wang, J., Sands, J. M., & Klein, J. D. (2016) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2016.08.015 · Cited by 68
“In clinical trials of dapagliflozin in patients with T2DM, although the number of events of hypovolemia was elevated in the dapagliflozin group versus the placebo group, the overall rates of volume-related events were low, and serum electrolytes were mostly unchanged[10].”
BackgroundKanie, T., Mizuno, A., Takaoka, Y., Suzuki, T., Yoneoka, D., Nishikawa, Y., Tam, W. W. S., Morze, J., Rynkiewicz, A., Xin, Y., et al. (2021) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd013650.pub2 · Cited by 111
Li, D., Liu, Y., Hidru, T. H., Yang, X., Wang, Y., Chen, C., Li, K. H. C., Tang, Y., Wei, Y., Tse, G., et al. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.619586 · Cited by 63
Spiazzi, B. F., Naibo, R. A., Wayerbacher, L. F., Piccoli, G. F., Farenzena, L. P., Londero, T. M., da Natividade, G. R., Zoldan, M., Degobi, N. A. H., Niches, M. D. S., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110621 · Cited by 63
Zhang, H., Ding, L., Mi, L., Zhang, A.-K., Zhang, K., Jiang, Z., Yu, F., Yan, X.-X., Shen, Y.-J., & Tang, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad356 · Cited by 58
Ghosh, R. K., Bandyopadhyay, D., Hajra, A., Biswas, M., & Gupta, A. (2016) · International Journal of Cardiology · doi:10.1016/j.ijcard.2016.02.134 · Cited by 53
“It had no adverse impact on CV safety when compared with placebo treatment [60].”
BackgroundTäger, T., Atar, D., Agewall, S., Katus, H. A., Grundtvig, M., Cleland, J. G. F., Clark, A. L., Fröhlich, H., & Frankenstein, L. (2020) · Heart Failure Reviews · doi:10.1007/s10741-020-09954-8 · Cited by 63
Fioretto, P., Mansfield, T. A., Ptaszynska, A., Yavin, Y., JOHNSSON, E. K., & Parikh, S. J. (2016) · Drugs & Aging · doi:10.1007/s40266-016-0382-1 · Cited by 63
Self-citationSGLT2i effect on atrial fibrillation: A network meta‐analysis of randomized controlled trials
Mariani, M. V., Manzi, G., Pierucci, N., Laviola, D., Piro, A., D’Amato, A., Filomena, D., Matteucci, A., Severino, P., Miraldi, F., et al. (2024) · Journal of Cardiovascular Electrophysiology · doi:10.1111/jce.16344 · Cited by 52
Myocardial metabolism in heart failure: Purinergic signalling and other metabolic concepts
Birkenfeld, A. L., Jordan, J., Dworak, M., Merkel, T., & Burnstock, G. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.08.015 · Cited by 51
Toto, R. D., Goldenberg, R., Chertow, G. M., Cain, V. A., Stefánsson, B. V., Sjöström, C. D., & Sartipy, P. (2019) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2019.06.007 · Cited by 50
Hu, M., Cai, X., Yang, W., Zhang, S., Nie, L., & Ji, L. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.015323 · Cited by 48
Terauchi, Y., Tamura, M., Senda, M., Gunji, R., & Kaku, K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12957 · Cited by 48
Kani, R., Watanabe, A., Miyamoto, Y., Ejiri, K., Iwagami, M., Takagi, H., Slipczuk, L. N., Tsugawa, Y., Aikawa, T., & Kuno, T. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.031805 · Cited by 49
Leiter, L. A., Cefalu, W. T., de Bruin, T. W., Xu, J. L., Parikh, S. J., JOHNSSON, E. K., & Gause‐Nilsson, I. A. M. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12666 · Cited by 44
“Statistical methods for the trials have been published previously [19,20].”
BackgroundMethodInfluentialSelf-citationRizzi, M., & Trevisan, R. (2016) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2016.07.006 · Cited by 42
Efficacy and safety of dapagliflozin in patients with type 2 diabetes and concomitant heart failure
Kosiborod, M., Gause‐Nilsson, I. A. M., Xu, J. L., Sonesson, C., & JOHNSSON, E. K. (2017) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2017.02.001 · Cited by 46
Self-citationJohnsson, K. M., JOHNSSON, E. K., Mansfield, T. A., Yavin, Y., Ptaszynska, A., & Parikh, S. J. (2016) · Postgraduate Medicine · doi:10.1080/00325481.2016.1153941 · Cited by 40
“High CV risk add-on to usual care NCT01031680 [20] 922 Dapagliflozin 10 mg Placebo OADs ± insulin”
BackgroundSelf-citationConsoli, A., Formoso, G., BALDASSARRE, M. P. A., & Febo, F. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1428305 · Cited by 44
“Indeed, hypoglycemia incidence in diabetic patients treated with GLP-1RA (exenatide LAR [10], dulaglutide [11], liraglutide [12], lixisenatide [13]) or SGLT2i (empaglifozin [14], dapaglifozin [15], canaglifozin [16]) was, in several trials where the agents were not used in association with insulin and/or sulfonylureas…”
BackgroundPalanisamy, S., Yien, E. L. H., Shi, L., Yi, L., Qi, S. H., Soon, L., Lun, T. W., & Chen, Y. N. (2018) · Pharmacy · doi:10.3390/pharmacy6030057 · Cited by 47
“[24] Multicenter, randomized, double-blind, placebo-controlled, international, phase 3 study Dapagliflozin group: mean age 62.”
Quagliariello, V., Canale, M. L., Bisceglia, I., Iovine, M., Paccone, A., Maurea, C., Scherillo, M., Merola, A., Giordano, V., Palma, G., et al. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1289663 · Cited by 48
Scheerer, M. F., Rist, R., Proske, O., Meng, A., & Kostev, K. (2016) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s116243 · Cited by 34
“46%).(20) In this real-world study, a greater HbA1c reduction was found in patients treated in diabetologist practices.”
BackgroundRole of SGLT1 in high glucose level-induced MMP-2 expression in human cardiac fibroblasts
Meng, L., Uzui, H., Guo, H., & Tada, H. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.8688 · Cited by 36
“In addition, Cefalu et al (6), showed that dapagliflozin plays a significant role in the reduction of HbA1c, BW, and SBP.”
Täger, T., Frankenstein, L., Atar, D., Agewall, S., Frey, N., Grundtvig, M., Clark, A. L., Cleland, J. G. F., & Fröhlich, H. (2021) · Clinical Research in Cardiology · doi:10.1007/s00392-021-01913-z · Cited by 39
Sciacqua, A., Succurro, E., Armentaro, G., Miceli, S., Pastori, D., Rengo, G., & Sesti, G. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10182-x · Cited by 38
Li, C. X., Liu, L. Y., Zhang, C. X., Geng, X. H., Gu, S. M., Wang, Y. Q., Liu, H., Xie, Q., & Liang, S. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1238399 · Cited by 45
“Acute kidney injury (23, 45, 54, 55, 67, 111, 114, 117, 118) SGLT-2is 9(4 register) was included in NMA 25748/19195 506(1.”
BackgroundClaerhout, B., Kalra, D., Mueller, C., Singh, G., Ammour, N., Meloni, L., Blomster, J., Hopley, M. J., Kafatos, G., Garvey, A., et al. (2019) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2018.12.004 · Cited by 38
Sodium-Glucose Cotransporter 2 Inhibitors and the Risk of Pneumonia and Septic Shock
Li, H., Tse, Y.-K., Chandramouli, C., Hon, N. W. L., Cheung, C., Lam, L.-Y., Wu, M., Huang, J.-Y., Yu, S.-Y., Leung, K. L. C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac558 · Cited by 35
Li, F.-F., Gao, G., Li, Q., Zhu, H., Su, X., Wu, J.-D., Ye, L., & Ma, J. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5347262 · Cited by 39
“Also, chronic hyperglycemia has been demonstrated to be a risk factor for developing CVD [29, 30].”
BackgroundNaeimzadeh, Y., Tajbakhsh, A., Nemati, M., & Fallahi, J. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176803 · Cited by 37
SGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Shi, N., Shi, Y., Xu, J., Si, Y.-X., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.668368 · Cited by 39
“(24) Multicenter NCT01031680 cerebrovascular disease; hypertension 52 Dapagliflozin 10mg Placebo”
BackgroundNatale, P., Tunnicliffe, D. J., Toyama, T., Palmer, S. C., Saglimbene, V. M., Ruospo, M., Gargano, L., Stallone, G., Gesualdo, L., & Strippoli, G. F. (2024) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd015588.pub2 · Cited by 69
SGLT2 inhibitors in hypertension: Role beyond diabetes and heart failure
Gupta, R., Maitz, T., Egeler, D., Mehta, A., Nyaeme, M. S., Hajra, A., Goel, A., Sreenivasan, J., Patel, N., & Aronow, W. S. (2022) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2022.05.005 · Cited by 37
Odutayo, A., da Costa, B. R., Pereira, T. V., Garg, V., Iskander, S., Roble, F., Lalji, R., Hincapié, C. A., Akingbade, A., Rodrigues, M., et al. (2021) · Journal of the American Heart Association · doi:10.1161/jaha.120.019918 · Cited by 29
Yoon, J., Min, S. H., Ahn, C. H., Cho, Y. M., & Hahn, S. (2018) · Scientific Reports · doi:10.1038/s41598-018-22443-1 · Cited by 31
Cintra, R. M. R., Moura, F. A., de Carvalho, L. S. F., Barreto, J., Tambascia, M. A., Pecoits‐Filho, R., & Sposito, A. C. (2019) · Revista da Associação Médica Brasileira · doi:10.1590/1806-9282.65.1.70 · Cited by 32
Yang, W., Cai, X., Gao, X., Chen, Y., Chen, L., & Ji, L. (2017) · Journal of Diabetes Investigation · doi:10.1111/jdi.12764 · Cited by 29
Sodium-Glucose Cotransporter-2 Inhibitors and Arrhythmias
Jaiswal, V., Ang, S. P., Kumar, D., Deb, N., Jaiswal, A., Joshi, A., NASIR, Y. M., Bandyopadhyay, D., Michos, E. D., Benjamin, E. J., et al. (2025) · JACC Advances · doi:10.1016/j.jacadv.2025.101615 · Cited by 31
Tseng, P., Zeng, B., Hsu, C.-W., Hung, C., Carvalho, A. F., Stubbs, B., Chen, Y., Chen, T., Lei, W., Chen, J.-J., et al. (2025) · BMC Medicine · doi:10.1186/s12916-025-04018-w · Cited by 36
Ong, H. T., Teo, Y. H., Teo, Y. N., Syn, N. L. X., Wee, C. F., Leong, S., Yip, A. S. Y., See, R. M., Ting, A. Z. H., Chia, A. Z. Q., et al. (2021) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2021.106159 · Cited by 30
Zheng, Z., He, D., Chen, J., Xie, X., Lu, Y., Wu, B., & Jiang, X. (2023) · Clinical Drug Investigation · doi:10.1007/s40261-023-01256-9 · Cited by 33
Heerspink, H. J. L., Sjöström, C. D., Inzucchi, S. E., Hallow, K. M., Cain, V. A., Rossing, P. R., Stefánsson, B. V., & Sartipy, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13579 · Cited by 24
“Two studies enrolled patients at high cardiovascular risk.(8,9) Detailed methods for individual trials have been described previously.”
Bae, J. H., Park, E.-G., Kim, S., Kim, S. G., Hahn, S., & Kim, N. H. (2021) · Endocrinology and Metabolism · doi:10.3803/enm.2020.912 · Cited by 31
“We included RCTs with a duration of 12 weeks or longer.”
BackgroundMethodInfluentialRong, X., Zhu, Y., Bo, W., Liu, K., Li, X., Gou, Q., & Chen, X. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.973129 · Cited by 30
“(33) NCT01064414 26weeks CANA 100mg, 300mg PLA 90, 89 90 69.”
The dawn of the four-drug era? SGLT2 inhibition in heart failure with reduced ejection fraction
Genuardi, M. V., & Mather, P. J. (2021) · Therapeutic Advances in Cardiovascular Disease · doi:10.1177/17539447211002678 · Cited by 27
Tsai, P.-C., Chuang, W.-J., Ko, A. M., Chen, J.-S., Chiu, C., Chen, C., & Yeh, Y. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-01789-5 · Cited by 26
“Five of the 43 studies Lavalle‑González et al., 2013 [33] 1101 (705/396) 549 (266/283) 55.4 (9.3) 54.7 (9.7) Canagliflozin (100/300 mg)/Placebo and Sitagliptin Metformin Cefalu et al., 2013 [34] 968 (493/475) 482 (238/244) 58.9 (9.4) 56.3 (9.0) Canagliflozin (100/300 mg)/Glimepiride Metformin NCT01106690, 2013 227 (14…”
BackgroundInfluentialMellander, A., Billger, M. A., JOHNSSON, E. K., Träff, A. K., Yoshida, S., & Johnsson, K. M. (2016) · Clinical Drug Investigation · doi:10.1007/s40261-016-0438-3 · Cited by 25
Wang, A., Yang, K., Wang, T., Zhang, N., Tang, H., & Feng, X. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3174 · Cited by 22
Yoosuf, B. T., Muhammed Favas, K. T., Spoorthy, D. P., Saini, A., Garg, P., Medenica, S., Dutta, P. R., & Bansal, D. (2025) · Endocrine · doi:10.1007/s12020-025-04393-7 · Cited by 24
Liu, J., Pong, A., Gallo, S., Darekar, A., & Terra, S. G. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0856-7 · Cited by 21
“It has been suggested that treatment with SGLT2 inhibitors may contribute to diuresis-induced hypovolemia [11, 12, 44, 45], and it could be speculated that this might add to risks from the use of antihypertensive therapies in this patient population.”
Scholtes, R. A., van Raalte, D. H., Correa‐Rotter, R., Toto, R. D., Heerspink, H. J. L., Cain, V. A., Sjöström, C. D., Sartipy, P., & Stefánsson, B. V. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13923 · Cited by 20
Tang, H.-L., Yang, K.-M., Song, Y., & Han, J.-L. (2018) · Diabetes, obesity and metabolism · doi:10.1111/dom.13474 · Cited by 16
Tayek, J. A. (2018) · Journal of Diabetes Metabolic Disorders & Control · doi:10.15406/jdmdc.2018.05.00148 · Cited by 24
Avogaro, A., Giaccari, A., Fioretto, P., Genovese, S., Purrello, F., Giorgino, F., & Prato, S. D. (2017) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2017.1322507 · Cited by 17
“factors: hyperglycemia, body weight, and BP [54,55], the triad”
BackgroundDapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
Saleem, F. (2017) · Cureus · doi:10.7759/cureus.1751 · Cited by 32
Taylor, K., McLellan, J., Verbakel, J. Y. J., Aronson, J. K., Lasserson, D. S., Pidduck, N., Roberts, N. W., Fleming, S., O’Callaghan, C. A., Bankhead, C. R., et al. (2019) · BMJ Open · doi:10.1136/bmjopen-2019-030596 · Cited by 18
Durability of response to dapagliflozin: a review of long-term efficacy and safety
Jabbour, S. A. (2017) · Current Medical Research and Opinion · doi:10.1080/03007995.2017.1354822 · Cited by 17
“In the study of Cefalu et al.(25), the mean placebo-subtracted seated reduction in SBP was statistically significant at week 8 (–1.”
BackgroundNovel Antidiabetic Drugs and Risk of Venous Thromboembolism: A Literature Review
Chen, Q., Anijs, R. J. S., Verlaan, J. P. L., Scheres, L. J. J., Klok, F. A., & Cannegieter, S. C. (2025) · Seminars in Thrombosis and Hemostasis · doi:10.1055/a-2546-0353 · Cited by 15
Wang, Y., Shao, X., & Liu, Z. (2022) · Endocrine Journal · doi:10.1507/endocrj.ej21-0616 · Cited by 12
“Finally, 13 articles [7, 15, 19-29] were included in our meta-analysis (Fig.”
BackgroundInfluentialIs there any robust evidence showing that SGLT2 inhibitor use predisposes to acute kidney injury?
Çöpür, S., Yıldız, A. B., Basile, C., Tuttle, K. R., & Kanbay, M. (2022) · Journal of Nephrology · doi:10.1007/s40620-022-01422-w · Cited by 18
Scorsone, A., Saura, G., Fleres, M., Spanò, L., Aiello, V., Brancato, D., Noto, A. D., Provenzano, F., & Provenzano, V. (2018) · Journal of Diabetes Research · doi:10.1155/2018/8501418 · Cited by 12
Xu, B., Kang, B., & Zhou, J. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02386-6 · Cited by 12
Metadata
- Authors
- Cefalu, W. T., Leiter, L. A., de Bruin, T. W. A., Gause-Nilsson, I., Sugg, J., & Parikh, S. J.
- Affiliations
- Pennington Biomedical Research Center (US)
- St. Michael's Hospital (CA)
- AstraZeneca, Global Medicines Development, Gaithersburg, MD
- AstraZeneca, Global Medicines Development, Mölndal, Sweden
- AstraZeneca (United States) (US)
- Corresponding author
- Cefalu, William T.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2015-04-07
- Volume
- 38
- Issue
- 7
- Pages
- 1218-1227
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC4831907
- OpenAlex
- W2076506641
- Cited by
- 182
- References
- 29
- Citations by year
- 2026: 14 · 2025: 15 · 2024: 24 · 2023: 12 · 2022: 15 · 2021: 20 · 2020: 10 · 2019: 16 · 2018: 14 · 2017: 17 · 2016: 20 · 2015: 5
- FWCI
- 16.19
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Diabetes Care (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- AstraZeneca
- GlaxoSmithKline
- Sanofi
- Intarcia Therapeutics
- MannKind Corporation
- Halozyme
- Novo Nordisk
- Servier
- National Institutes of Health
- National Institute of General Medical Sciences (104940, GM104940, U54GM104940)
- Janssen Biotech
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- dapagliflozin, SGLT2 inhibitors, type 2 diabetes, glycemic control, cardiovascular risk, hypertension, HbA1c, weight loss, systolic blood pressure, insulin dose reduction, adverse events, renal failure, urinary tract infection, older adults, cardiovascular safety, high-risk patients, hypoglycemia
- MeSH terms
- Analysis of Variance, Benzhydryl Compounds, Blood Glucose, Blood Pressure, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Double-Blind Method, Female, Glucosides, Glycated Hemoglobin, Humans, Hypoglycemia, Hypoglycemic Agents, Insulin, Male, Middle Aged, Risk Factors, Urinary Tract Infections, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.